Actively Recruiting
Phase 3 Study of Iptacopan to Evaluate Safety and How It Works in Children 2 to Under 18 Years with Paroxysmal Nocturnal Hemoglobinuria
Led by Novartis Pharmaceuticals · Updated on 2026-08-07
12
Participants Needed
15
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
The trial investigates the pharmacokinetics, safety, and tolerability of iptacopan in children aged 2 to under 18 years who have paroxysmal nocturnal hemoglobinuria PNH. It is a phase 3, open-label, single-arm, multicenter study designed to better understand how this drug behaves and is tolerated in pediatric patients with this condition. Participants are grouped into three age cohorts adolescents 12 to under 18 years, children 6 to under 12 years, and young children 2 to under 6 years. Those 12 to under 18 years receive a fixed dose of 200 mg twice daily, while younger participants have doses adjusted by weight at multiple points during the study. The study consists of an up to 8-week screening period, a 26-week treatment period, and a 26-week extension treatment period. Throughout the study, children will be closely monitored through blood tests and clinical assessments to track drug levels and safety, including the occurrence of adverse events. Researchers will measure changes in hemoglobin and lactate dehydrogenase levels. Vaccinations are required before treatment, and the total participation time may last up to about 60 weeks including screening and treatment phases.
CONDITIONS
Brief Title
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here